This website uses cookies to help us give you the best browsing experience. By continuing to use this portal, you agree to our use of this tool.
To learn more about how we use cookies and how to manage them please read our notice here.
Tip of the Month
Tip of the month - Avoid the upper nasal quadrant when inserting an aqueous drainage implant, as it can result in acquired Brown syndrome
Avoid the upper nasal quadrant when inserting an aqueous drainage implant, as it can result in acquired Brown syndrome

Publishing date: November 2015


The science behind the tip

Aqueous drainage tubes are commonly used in the surgical treatment of refractory glaucoma.  New onset persistent diplopia may follow in 5% of patients (1).  This complication has been reported in all types of tube and valved implants and probably represents a persistent lengthwise stretching of the extraocular muscles by an underlying bleb or scarring between the muscle and the underlying implant.

If the tube is inserted in the upper nasal quadrant, it can cause diplopia secondary to acquired Brown syndrome (limitation of elevation in adduction) as a consequence of fibrotic shortening of the superior oblique tendon (2).  Factors that may reduce the risk of motility disturbance include careful surgical technique; reduced implant size, and avoidance of the upper nasal quadrant when placing the tube (1,3).

Contributor: J F Salmon MD Consultant Ophthalmologist - Oxford Eye Hospital (UK)


References:

1. Rauscher FM, Gedde SJ et al.  Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up.  Am J Ophthalmol 2009; 147: 458-466

2. Dobler-Dixon AA, Cantor LB, Sondhi et al.  Prospective evaluation of extraocular motility following double-plate Molteno implantation.  Arch Ophthalmol 1999; 117:  1155-1160

3. Harbick KH, Sidoti PA, Budenz DL et al.  Outcomes of inferonasal Baerveldt glaucoma drainage implant surgery.  J Glaucoma 2006; 15: 7-12


Tip Reviewer: Roger Hitchings
Tip Editors: John Salmon and Gordana Sunaric Mégevand





back to top
X